The treatment armamentarium for renal cell carcinoma mainly comprises small-molecule antiangiogenic inhibitors and immune checkpoint inhibitors. Bristol-Myers Squibb/Ono Pharmaceutical’s PD-1 inhibitor Opdivo, which was approved for this indication as monotherapy in 2015 and in combination with the CTLA-4 inhibitor Yervoy in 2018, has revolutionized clinical practice. Although existing treatment options aim to improve PFS, significant need remains for well-tolerated therapies that can extend the OS and PFS of patients with advanced or metastatic renal cell carcinoma.
- What are the treatment drivers that are most likely to influence a therapy’s uptake for advanced or metastatic renal cell carcinoma?
- How do current therapies for advanced or metastatic renal cell carcinoma perform on key attributes?
- What are the prevailing areas of unmet need and hidden opportunities in this patient population?
- What trade-offs are surveyed medical oncologists willing to make across key clinical attributes and price when considering hypothetical new treatment options for advanced or metastatic renal cell carcinoma?
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
- Renal Cell Carcinoma - Unmet Need - Detailed, Expanded Analysis: Metastatic Renal Cell Carcinoma
Author(s): Khurram Nawaz, MSc
Khurram Nawaz is a director in the oncology team at Decision Resources Group. Mr. Nawaz manages a team of analysts who conduct extensive primary and secondary market research on several oncology indications across the major pharmaceutical markets. He also provides sales and client support on syndicated and custom oncology products, translating domain knowledge into actionable insights.
Previously, Mr. Nawaz was a principal analyst in the oncology team at Decision Resources Group, where he developed considerable expertise in forecasting complex oncology and hemato-oncology drug markets, and conducted detailed primary research with physicians and payers across multiple geographies. He has in-depth expertise in immuno-oncology, non-small-cell lung cancer, prostate cancer, multiple myeloma, and other solid and hematological malignancies. Prior to joining Decision Resources Group, Mr. Nawaz was a scientist at GlaxoSmithKline, where he contributed to the development of candidate drugs for schizophrenia and cognitive disorders. He holds a M.Sc. in biotechnology from the École Supérieure d'Ingénieurs de Luminy (now Polytech Marseille), University of Aix-Marseille, and a B.Sc. in life sciences from the Pierre and Marie Curie–Paris VI University.